Shares of Inovio Pharmaceuticals INO moved higher in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were up 63.16% over the past year to ($0.14), which beat the estimate of ($0.22).
Revenue of $5,581,000 rose by 1900.36% year over year, which beat the estimate of $1,110,000.
Looking Ahead
Inovio Pharmaceuticals hasn't issued any earnings guidance for the time being.
Inovio Pharmaceuticals hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Mar 01, 2021
Time: 04:30 PM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2021/40128
Price Action
52-week high: $33.79
52-week low: $3.73
Price action over last quarter: Up 4.26%
Company Profile
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
